News (1) to (2) / Editor : Liao Peiqi / Translation, editing : Gan Yung Chyan, KUCINTA SETIA
News (1)
Introducing Japan's covi vaccines
AnGes: Osaka Biotech AnGes is the first gene therapy company in Japan. They have conducted clinical trials with 500 people and developed a DNA vaccine against covid. In the report meeting yesterday (4), they stated that they have entered the final stage of clinical trials, and Professor Ryuichi Morishita, who is in charge of the lead, disclosed the initial test results. The AnGes vaccine has passed the test in terms of immunity and safety, and it is expected that it will be tested in the summer. The production of tens of millions of doses of the AnGes covi vaccine is hailed as the "vaccine pioneer" by Japanese media.
Shionoyoshi Pharmaceutical: The first domestic covi vaccine from a large Japanese pharmaceutical company has entered clinical trials. On 16 December 2020, 214 people participated in the clinical trial. It uses insect cell and other protein expression technology to produce recombinant protein antigens to manufacture vaccines. In May 2021, it was announced that there is no safety issue in the use of the vaccine. After July 2021, further analysis will be made on whether sufficient antibodies can be produced to drive the immune part. It is expected that the vaccine will be available this year.
Daiichi Sankyo: The company produces the "DS-5670" vaccine that uses the same mRNA components as Pfizer-BioNTech. DS-5670 is developed using Daiichi Sankyo’s proprietary new nucleic acid delivery technology. Phase 1/2 clinical trials began in March 2021. The initial clinical trial results proved that DS-5670 has good safety and effectiveness. Since Japan purchased 120 million doses of vaccines from AZ, Daiichi Sankyo was also commissioned by the government in addition to its own vaccines and announced the start of mass production of AZ vaccines in March.
KM Biologics: KM Biologics, a company located in Kumamoto, also conducted clinical trials on 210 participants on 22 March 2021. The vaccine produced by the company uses an "inactivated vaccine" that can kill the virus by processing the virus. It is the same as seasonal influenza and other vaccines, but it is not expected to be practical until 2023.
ID Pharma: "ID Pharma", a subsidiary of I'rom Group, agreed in February 2021 to jointly develop a new vaccine with the Shanghai Public Health Clinical Center. The "Viral vector vaccine" it studied is a virus. The carrier delivers the genetic material of the synthetic antigen to the human host cell vaccine. It is estimated that animal experiments can be conducted in China as early as July.
Takeda Pharmaceutical Industry: Takeda Pharmaceutical Industry Co., Ltd. previously conducted clinical trials and investigated the effectiveness and safety of vaccines produced by Moderna with 200 people over the age of 20. After the test results were obtained, the Ministry of Health, Labour and Welfare approved Takeda’s products. The vaccine will be available immediately in Japan.
Tanabe Mitsubishi Pharmaceuticals: Tanabe’s Canadian subsidiary Medicago announced in March that it will use special plant platform technology to develop covi vaccines. It is expected to start human trials in July or August. As for whether the vaccine can be used in Japan it is currently under review. In addition to domestic vaccines, Japan also cooperates with foreign countries to produce AZ and Moderna vaccines.
In addition to the above seven vaccines, VLP Therapeutics Japan Group is also excited to introduce at the meeting that only a small amount of RNA can be used to create a new vaccine with the same effect. It is expected that a specific clinical trial plan will be planned in the middle of June 2021 for submission to the Japanese government.
News (2)
Japan has discovered a new mutant strain C36. Governor Koike pleads for self-reliance and avoids going out
Tokyo Metropolitan Government announced in an online conference on 4 June 2021 that a new variant of a virus that has never appeared in Japan was found in the Japanese airport upon traveler quarantine, suspected to be a "C36" covi mutant strain.
According to the Japanese media NHK, the virus was detected in a 50-year-old man who returned from North Africa last month. After investigation by the Tokyo Metropolitan Research Center, the "C36" virus is likely to have appeared in Japan for the first time.
The man who returned to Japan from North Africa last month had a negative initial quarantine result but he developed symptoms of infection during isolation at home. After testing, it was found that he was infected with a mutant virus characteristic of the Indian mutant strain "L452R". Some of the Indian variant viruses have characteristics, but the variant virus lacks the "Peplomer" component called "C36".
So far, the "C36" mutant strain has been discovered in 34 countries including the United Kingdom and the United States. However, since it is still unclear what its true form is, there is no way to confirm its related information. However, in the future, Tokyo will cooperate with the Japanese government on studies of this new covi variant.
There are currently 28 people infected with Covi72 in Tokyo. The main pandemic virus in Japan is the "N501Y" . The positive diagnosis rate has increased compared with the previous week. 1 percentage point, that is, 83% of all confirmed cases are infected with N501Y.
As of 7.30 pm on 4 June, 2,595 people were infected in a single day across Japan, and 86 people died. There were 472 people in Tokyo, 189 people in Osaka, 247 people in Okinawa, and 203 people in Hokkaido.
Japanese media reported that the average number of infections in Tokyo during these 7 days has been on the decline, and it is improving from the fourth level of the "infection outbreak stage" to the third level of the "infection surge stage", but all are going out inside and out. The crowds have surged for three consecutive weeks, especially the number of people who go out after 8 pm. Therefore, Governor Koike said three times in a row that "ten thousand, ten thousand, do not go out, I hope everyone will follow."
No comments:
Post a Comment